Articles related to COLORECTAL CANCER (CRC)

The recent phase 3 trial has demonstrated that the combination of the KRAS G12C inhibitor, sotorasib, with the EGFR inhibitor, panitumumab, can lead to longer progression-free survival in patients with chemorefractory metastatic colorectal cancer.

With a negative predictive value of 97%, the new breath test for colorectal cancer represents a significant advancement in non-invasive cancer diagnostics.

Test your knowledge and clinical acumen with this quiz, featuring a case study on chemotherapy regimens for metastatic adenocarcinoma of the colon.

New research questions the life-extending efficacy of most common cancer screenings, emphasizing the need for transparent physician-patient discussions to weigh the risks and benefits. Learn more about this crucial topic that might change your approach to recommending screenings.

Explore the phase 1 study findings on Divarasib, a covalent KRAS G12C inhibitor, which has shown durable clinical responses with a favorable safety profile in patients with KRAS G12C-positive tumors.

The IDEA study’s findings have led to a notable change in the treatment of stage III colon cancer, with a shift towards a 3-month duration using CAPOX. Explore the detailed analysis and its implications for your practice.